Leerink Partners analyst David Risinger has maintained their bullish stance on BMY stock, giving a Buy rating on November 19.Don't Miss our ...

Black Gotham Experience (BGX), the Lower Manhattan-based immersive visual storytelling project that commemorates the impact ...

The Greyhounds have shrugged off a slow start and are now above .500 for the first time this season, having won three ...

Leerink analyst David Risinger upgraded AbbVie (ABBV) to Outperform from Market Perform with a $206 price target The firm ...

This Tuesday, Nov. 19, the Career and Professional Development Center hosted a Professional Panel Series titled “New ...

Sagittarius A* has been seen by human eyes with an "image produced by a global research team called the Event Horizon ...

BY DIANNA RISINGER Times-Democrat News Staff Piggott and the nation paused on Monday, Nov. 11, as Veterans Day 2024 was ...

Suffer tough loss in final game ...

The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

The drug, called icotrokinra and developed together with Protagonist Therapeutics, is an oral peptide designed to tamp down ...

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), retaining the price target of ...